Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Patriot Financial Group Insurance Agency LLC

by · The Cerbat Gem

Patriot Financial Group Insurance Agency LLC raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 9.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,384 shares of the pharmaceutical company’s stock after acquiring an additional 302 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Vertex Pharmaceuticals were worth $1,574,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in VRTX. Northwest Investment Counselors LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth $25,000. GHP Investment Advisors Inc. purchased a new position in Vertex Pharmaceuticals in the 2nd quarter worth about $29,000. Stephens Consulting LLC acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth about $31,000. Founders Capital Management lifted its stake in Vertex Pharmaceuticals by 50.0% during the second quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 25 shares in the last quarter. Finally, ZRC Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals in the first quarter worth about $39,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.3 %

VRTX traded down $1.51 on Monday, hitting $476.19. The company had a trading volume of 138,151 shares, compared to its average volume of 1,166,140. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average price is $475.61 and its 200 day moving average price is $462.73. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $510.64.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The firm had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.66 billion. During the same quarter in the previous year, the firm posted $3.53 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 6.1% compared to the same quarter last year. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -2.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on VRTX shares. UBS Group upped their price target on shares of Vertex Pharmaceuticals from $477.00 to $562.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. HC Wainwright restated a “buy” rating and issued a $600.00 target price on shares of Vertex Pharmaceuticals in a report on Monday, October 21st. Truist Financial reiterated a “buy” rating and set a $550.00 price target (up previously from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. StockNews.com downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 5th. Finally, Raymond James restated a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $492.92.

View Our Latest Report on Vertex Pharmaceuticals

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the sale, the director now owns 40,000 shares of the company’s stock, valued at $20,320,000. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares in the company, valued at approximately $2,217,500. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce I. Sachs sold 5,295 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the transaction, the director now owns 40,000 shares in the company, valued at $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,005 shares of company stock valued at $5,988,066. Insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read More